IDH1 R132G mutation (glioma / AML)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-IDH1-R132G |
|---|---|
| Type | Biomarker |
| Aliases | IDH1 R132GМутація IDH1 R132G (гліома / ГМЛ) |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-EANO-GBM-2024 SRC-ESMO-AML-2020 SRC-NCCN-CNS-2025 |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Mutation details | {"exon": "4", "functional_impact": "neomorphic — converts α-KG to 2-hydroxyglutarate (oncometabolite); DNA hypermethylation", "gene": "IDH1", "hgvs_protein": "p.R132G", "variant_type": "missense"} |
| Measurement | MethodNGS panel (R132G is IHC-negative with the R132H-specific antibody — requires sequencing). Co-call with TMB / methylation profiling where available. Unitscategorical (positive | negative) |
| Actionability lookup | {"gene": "IDH1", "variant": "R132G"} |
| Related biomarkers | BIO-IDH1-R132H BIO-IDH-MUTATION BIO-MGMT-METHYLATION |
Notes
Less prevalent IDH1 variant (~3-5% of IDH1-mutant glioma; rarer in AML and cholangiocarcinoma). IHC-negative with the R132H-specific antibody (clone H09) — NGS required. On the ivosidenib hotspot list alongside R132H/R132C/R132L/R132S; reuses existing REG-IVOSIDENIB and IDH1-keyed indications. Vorasidenib (INDIGO 2024 — grade 2 IDH-mut glioma post-resection) covers IDH1/IDH2 variants broadly. Engine should treat as functionally equivalent to R132H for ICI / IDH-i treatment selection logic.
Used By
Indications
IND-AML-RR-IDH1-OLUTASIDENIB- IND-AML-RR-IDH1-OLUTASIDENIB